• capecitabine
  • Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. (nih.gov)
  • The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an acceptable regimen with or without adding cisplatin. (nih.gov)
  • Patients with advanced, unresectable NETs of pancreatic, gastrointestinal foregut or unknown primary site were randomised to receive three-weekly capecitabine (Cap) 625 mg/m(2) twice daily orally, streptozocin (Strep) 1.0 g/m(2) intravenously on day 1, with or without cisplatin (Cis) 70 mg/m(2) intravenously on day 1. (nih.gov)
  • people
  • Streptozocin is prescribed to help prevent cancer cells from growing and multiplying in people who have a certain type of pancreatic cancer. (emedtv.com)
  • Streptozocin is reserved for use in people who are having symptoms or who have cancer that has spread to other areas of the body (metastasized) and is continuing to progress. (emedtv.com)